Impact of the Lilly SP‐X p ‐tau217 plasma assay on management of patients with cognitive impairment: results of a clinical utility study in an ethnically and racially representative cohort, Lilly J4Y‐MC‐B002

Abstract

Background: Diagnostic criteria for Alzheimer's disease (AD) include confirmation of amyloid pathology. The Lilly SP‐X p ‐tau217 plasma assay presents a minimally invasive biomarker to identify amyloid pathology; however, clinical utility of plasma biomarkers for patients presenting with cognitive impairment (CI) is not fully understood.

The paper